Avenue Therapeutics
menu
  • About
    • Management Team
    • Board of Directors
    >
  • Pipeline
    • BAER-101
    • IV Tramadol
    • AJ201
    >
  • Publications
  • Investors
    • News & Events
      • Overview
      • Press Releases
      • IR Calendar
      • Email Alerts
      >
    • Company Info
      • Overview
      • Management Team
      • Presentations
      • Contacts
      • FAQ
      >
    • Financial Info
      • Overview
      • Financial Results
      • Income Statement
      • Balance Sheet
      • Cash Flow
      • Analyst Coverage
      >
    • Stock Data
      • Quote
      • Charts
      • Historical Data
      >
    • SEC Filings
      • Overview
      • All SEC Filings
      • Annual Reports
      • Quarterly Reports
      • Section 16 Filings
      >
    • Governance
      • Overview
      • Board of Directors
      • Board Committees
      • Governance Documents
      >
    >
  • Events
  • Contact Us
    • Careers
      • Email Alerts
      >
    >

Press Releases

Investors

Investors

  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Analyst Coverage
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
      Nov 14, 2024

      Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

      Oct 09, 2024

      Avenue Therapeutics to Participate in Maxim Group’s 2024 Healthcare Virtual Summit

      Sep 03, 2024

      Avenue Therapeutics to Participate in Upcoming Investor Conferences

      Aug 09, 2024

      Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

      Jun 20, 2024

      Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

      May 16, 2024

      Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

      May 15, 2024

      Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

      Apr 29, 2024

      Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds

      Apr 24, 2024

      Avenue Therapeutics Announces Reverse Stock Split

      Mar 25, 2024

      Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024

      • 1
      • 2
      • 3
      • 4
      • 5
      • 6
      • 7
      • 8
      • 9
      • 10
      • arrow_forward
      rss_feed News RSS
      • Email Alerts
      • Contacts
      • RSS News Feed
      • Privacy
      • Disclaimer
      • Contact Us


      twitter icon linked-in icon
      Website Design, Maintenance and Hosting by Tidal Media Group
      Copyright ©2025 Avenue Therapeutics.

      logo